Pfizer to pay $400 million to avert investor class action trial
January 27, 2015 at 14:47 PM EST
NEW YORK, Jan 27 (Reuters) - Pfizer Inc said on Tuesday it agreed to pay $400 million to avert a trial in a class action lawsuit accusing the pharmaceutical giant of misleading investors in connection with off-label marketing.
